Metastatic Breast Cancer Research Conference
Friday–Saturday, September 12–13, 2014
Beller Conference Center, University of Kansas Medical Center, Kansas City, Kan.
Sponsored by Theresa’s Research Foundation and University of Kansas Medical Center Continuing Education & Professional Development
Danny R. Welch, PhD, Professor and Chair of Cancer Biology; Associate Director for Basic Sciences, University of Kansas Medical Center, Kansas City, Kan.
Jennifer R. Klemp, PhD, MPH, Associate Professor of Medicine; Managing Director, Breast Cancer Survivorship Center, University of Kansas Medical Center, Kansas City, Kan.
Metastatic, stage IV, or advanced breast cancers are defined by spread beyond the breast into other body systems. Metastases account for greater than 90 percent of cancer morbidity and mortality. This translates into nearly 40,000 deaths each year in the U.S. and approximately 500,000 worldwide. Metastatic breast cancer is the leading cause of cancer death in women under 50 years of age.
The Metastatic Breast Cancer Research Conference presents updates on basic science, clinical, and survivorship issues that relate to the development, treatment and sequelae of metastatic breast cancer. The integration of all three aspects is presented with the belief that all three phases are needed to understand and effectively treat metastatic breast cancer. The conference will also focus on collaborations.
This conference is designed for physicians, nurses, healthcare professionals, researchers and others who participate in the care of patients with breast cancer, especially metastatic cancer.
At the completion of this conference participants should be able to:
- Explain the role of mutations in breast cancer development, progression and metastasis
- Discuss the use of clinical trials in the treatment of metastatic breast cancer
- Identify appropriate patients for new and emerging therapies for metastatic breast cancer
- Describe the mechanism of action of immunotherapy agents
- Evaluate patients for surgical management
- Describe genotypic and phenotypic differences associated with triple negative breast cancers
- Discuss issues faced by metastatic patients and their caregivers
- Discuss survivorship issues, such as cardio-oncology and palliative care
Financial contributions and supporters of this program will be acknowledged in print at the conference.
Commercial vendors are invited to exhibit at this meeting. Limited exhibit space will be available. Contact Josh Newby at email@example.com